Sowell Financial Services LLC Takes $332,000 Position in argenex SE (NASDAQ:ARGX)

Sowell Financial Services LLC bought a new stake in shares of argenex SE (NASDAQ:ARGX - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The fund bought 561 shares of the company's stock, valued at approximately $332,000.

Several other institutional investors have also made changes to their positions in ARGX. GeoWealth Management LLC boosted its position in argenex by 56.3% in the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after buying an additional 18 shares in the last quarter. Whipplewood Advisors LLC acquired a new position in argenex in the fourth quarter valued at about $37,000. Global Retirement Partners LLC boosted its position in argenex by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after buying an additional 48 shares in the last quarter. FIL Ltd acquired a new position in argenex in the fourth quarter valued at about $38,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in argenex in the fourth quarter valued at about $38,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. HC Wainwright restated a "buy" rating and issued a $720.00 price target on shares of argenex in a research report on Tuesday, June 10th. Robert W. Baird upgraded shares of argenex from a "neutral" rating to an "outperform" rating and set a $680.00 target price on the stock in a research report on Tuesday, May 13th. Guggenheim reduced their target price on shares of argenex from $1,100.00 to $1,065.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Citigroup reiterated a "buy" rating on shares of argenex in a research report on Wednesday, May 21st. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of argenex from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. One research analyst has rated the stock with a hold rating, nineteen have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, argenex currently has an average rating of "Buy" and a consensus target price of $709.18.

argenex Stock Performance

Shares of NASDAQ:ARGX opened at $542.15 on Friday. argenex SE has a 52 week low of $428.76 and a 52 week high of $678.21. The company has a market capitalization of $33.10 billion, a PE ratio of 33.45, a PEG ratio of 0.98 and a beta of 0.39. The company has a 50 day moving average price of $585.62 and a two-hundred day moving average price of $609.06.

argenex (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.32 by $0.26. argenex had a net margin of 40.20% and a return on equity of 16.15%. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $748.34 million. On average, sell-side analysts forecast that argenex SE will post 3.13 earnings per share for the current year.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.